MyLeukemiaTeam

It's completely understandable to feel nervous about switching to a new medication, especially at 74. The symptoms being experienced — weight loss, fatigue, enlarged lymph nodes, and low appetite — are recognized signs that CLL may be progressing, which is likely why the doctor is recommending a change.

Brukinsa Show Full Answer

It's completely understandable to feel nervous about switching to a new medication, especially at 74. The symptoms being experienced — weight loss, fatigue, enlarged lymph nodes, and low appetite — are recognized signs that CLL may be progressing, which is likely why the doctor is recommending a change.

Brukinsa (zanubrutinib) belongs to a class of drugs called BTK inhibitors, which are a type of targeted therapy. Unlike traditional chemotherapy, targeted therapies are designed to attack cancer cells more directly by focusing on specific proteins inside leukemia cells. Here are some things worth knowing about Brukinsa as a targeted therapy:

- It works differently from Rituxan, targeting specific pathways that help CLL cells survive
- Targeted therapies like this tend to have a different — and sometimes more manageable — side effect profile compared to chemotherapy
- Common side effects can include fatigue, diarrhea, and increased infection risk
- It's important to discuss any concerns about tolerability with the doctor, especially regarding age-related considerations

It's worth having an open conversation with the oncologist about what to expect during the transition. Many MyLeukemiaTeam members have found that asking their care team detailed questions about side effects helped ease their anxiety about starting new treatments.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

4 Signs and 5 Symptoms of CLL

Chronic Lymphocytic Leukemia Treatment Options